Valerio Therapeutics (ALVIO) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Valerio Therapeutics stock €0.07, price €0.41, that is 82.7% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Valerio Therapeutics
ALVIO · PAFar too expensive (fair value 83% below the price), but company just good enough and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 18, 2026.
How to read this chart
60‑month range €0.0444 – €0.8780 · fair‑value band €0.0300 – €0.1200 · the €0.4055 price screens above the €0.0700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 18, 2026.
Every Wednesday you see whether Valerio Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Valerio Therapeutics, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies.
Show moreShow less
The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjugates, and chimeric antigen receptors.
The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics in June 2023. Valerio Therapeutics was incorporated in 1997 and is headquartered in Paris, France.
Stock analysis
Valerio Therapeutics (ALVIO) currently trades at €0.4055, while our model-based Fair Value estimate is €0.0700, 83% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €0.0900 per share, and 0 of the 3 models we run sit above the €0.4055 price.
Bear case: the DCF Models group reads lowest at €0.0550, and 3 of the 3 models stay below the price. Data coverage for this calculation is low.
Scenario range: €0.0300 (bear) to €0.1200 (bull), the price of €0.4055 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Valerio Therapeutics reported revenue of €2.6M in FY2025 versus €4.1M in FY2021, a compound −10.8%/yr. Reported net income was −€4.9M in FY2025.
Key figures
Market cap €247M Micro · P/S ratio 44.5 · EPS (TTM) €−0.0300 · Return on equity −732% · Return on assets (EBIT) −41.3% (5-year average) · Operating margin −50.4% · Revenue (TTM) €5.5M · Revenue growth (YoY) +23.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 283% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −83%, ALVIO screens richer than that median.
Fair Value models
All 8 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Compare Valerio Therapeutics with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- Stock screener with 62 metrics
- Undervalued stocks: French Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $957.76 | $1,275 | +33% | vs ALVIO |
| Vertex Pharmaceuticals Incorporated VRTX | $534.20 | $592.46 | +11% | vs ALVIO |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs ALVIO |
| argenx SE ARGX | $947.52 | $908.40 | −4% | vs ALVIO |
| CSL Limited CSL | A$199.38 | A$186.49 | −6% | vs ALVIO |
| Moderna, Inc MRNA | $206.80 | $135.64 | −34% | vs ALVIO |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs ALVIO |
| Revolution Medicines, Inc RVMD | $162.69 | $88.78 | −45% | vs ALVIO |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs ALVIO |
| Royalty Pharma plc RPRX | $68.68 | $19.01 | −72% | vs ALVIO |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Valerio Therapeutics (ALVIO) overvalued or undervalued?
What is the fair value of ALVIO?
What is the quality score of ALVIO?
What is the price target for Valerio Therapeutics (ALVIO)?
What is the Valerio Therapeutics stock forecast for 2026?
What is the revenue of Valerio Therapeutics (ALVIO)?
What growth is priced into Valerio Therapeutics (ALVIO)?
What discount rate (WACC) does the fair value of ALVIO use?
What is a reverse DCF?
How much growth has Valerio Therapeutics (ALVIO) delivered so far?
How fast is the sector of Valerio Therapeutics (ALVIO) growing?
What is the free cash flow yield of Valerio Therapeutics (ALVIO)?
What is the intrinsic value of Valerio Therapeutics (ALVIO)?
Is Valerio Therapeutics stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ALVIO?
How much is Valerio Therapeutics worth?
What do the bullish and bearish scenarios say about ALVIO?
What is the PEG ratio of ALVIO?
How solid is the balance sheet of Valerio Therapeutics (ALVIO)?
How far is ALVIO from its 52-week high?
Which stocks are comparable to Valerio Therapeutics?
Is Valerio Therapeutics stock attractive at the current price?
How is the fair value of ALVIO calculated?
Is it still worth investing in stocks now?
What is the share price of Valerio Therapeutics (ALVIO)?
What should I pay attention to with Valerio Therapeutics right now?
Key figures of Valerio Therapeutics
How large is the market capitalisation of Valerio Therapeutics (ALVIO)?
What is the P/S ratio of Valerio Therapeutics (ALVIO)?
What are the earnings per share of Valerio Therapeutics (ALVIO)?
What is the return on equity of Valerio Therapeutics (ALVIO)?
What is the EBIT return on assets of Valerio Therapeutics (ALVIO)?
What is the operating margin of Valerio Therapeutics (ALVIO)?
How fast is revenue growing at Valerio Therapeutics (ALVIO)?
How much net debt does Valerio Therapeutics (ALVIO) carry?
Watch Valerio Therapeutics in the live analysis
One click puts Valerio Therapeutics on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.